A Collaborative Community Effort using belantamab mafodotin in Relapsed/Refractory Myeloma

Clinical Trial Grant

Duke Scholars

Principal Investigator Cristiana A. Costa Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

March 3, 2023

End Date

February 28, 2030

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

March 3, 2023

End Date

February 28, 2030